In line with reduced adiposity and improved insulin sensitivity, FMTRYGB animals showed improved steatosis (Fig. 2j–k), reduction in lipid levels (Fig. 2l), and a switch to a dominant anti-inflammatory cytokine profile compared to HF-DIO controls (Fig. 2m). The gene discussed is INS; the disease is steatosis.